KBI Biopharma, Inc.
Raised $7,009,018
Series C Convertible Preferred Stock
-
KBI BioPharma, Inc. (“KBI” or the “Company”) was a rapidly growing contract biopharmaceutics, process development, and biomanufacturing services company. KBI was also developing its proprietary Centrifugal Bioreactor (“CBR”) technology, which would provide a revolutionary improvement in the processing of biological therapeutics.
-
KBI’s customers recognized that the Company was changing the paradigm of large molecule drug discovery and development. The Company’s current contract service business had pioneered a predictive approach to protein characterization, which combined the use of advanced biochemical and biophysical tools with statistical design to rapidly develop processes which maximized activity and stability of their customers’ products.
-
The market for recombinant protein therapeutics had grown dramatically in recent years. The biopharmaceutical market was valued at $70.8 billion in 2005, having grown 16.5% from 2004 revenues of $60.7 billion. Double digit growth of the market was expected to continue to the end of the decade.
KBI BioPharma, Inc. (“KBI” or the “Company”) was a rapidly growing contract biopharmaceutics, process development, and biomanufacturing services company that issued over $7,000,000 to fund working capital, applications development and commercialization activities.
Securities sold by affiliate, Carolina Financial Securities, LLC.
